Enhanced anti-tumor efficacy of tumor-infiltrating lymphocytes by GITR agonist in ovarian cancer
Taken together, we demonstrated that the addition of an agonistic GITR antibody during the early phase of TIL culture increased the CD8<sup>+</sup> T cell to Treg cell ratio and enhanced anti-tumor T cell immunity. Enhancing TILs with a GITR agonist may be beneficial for improving the clinical outcomes of TIL-based ACT in OC.
Authors
- Sohyun Hwang (ORCID: https://orcid.org/0000-0003-2461-6806)
- Ai Sim Goh (ORCID: https://orcid.org/0000-0002-1721-6778)
- Hee Jung An
- Eun Ji Lee (ORCID: https://orcid.org/0000-0002-4860-2495)
- Hyun Park (ORCID: https://orcid.org/0000-0002-7825-9165)
- Ji Min Lee (ORCID: https://orcid.org/0000-0003-2978-2440)
- Haeyoun Kang
- Ki Yeon Kim
- Daun Jung (ORCID: https://orcid.org/0000-0002-3507-9826)
Institutions
- CHA University Bundang Medical Center (KR)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-11-06
- DOI
- https://doi.org/10.3389/fimmu.2025.1670841
- Primary Topic
- Immunotherapy and Immune Responses
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Korea Health Industry Development Institute